TY - JOUR
T1 - Pregabalin Misuse
T2 - Motives, Pattern, and Knowledge about Its Risks among Patients in Methadone Maintenance Treatment
AU - Peles, Einat
AU - Sason, Anat
AU - Schreiber, Shaul
AU - Adelson, Miriam
N1 - Publisher Copyright:
© 2020 Taylor & Francis Group, LLC.
PY - 2021
Y1 - 2021
N2 - We examined motives for pregabalin misuse and the relation with knowledge on its risks among patients receiving MMT. A questionnaire was used to assess patients’ knowledge before and after an explanatory session. Responses were either “never-use” or “ever-use” (past, occasional, chronic). Pregabalin in urine was tested during 1 month, 4 months before, and 24 months after the explanatory session. Of 231 participants, 72 (31.2%) responded “ever-use” while 46 (19.9%) tested positive for pregabalin (42 (58.3%) of the “ever-use” and 4 (2.5%) of the “never-use” group). The ‘occasional’ subgroup had the highest proportion of non-prescribed pregabalin (75%), used it for recreational purpose (16.7%) and non-orally (41.7%). A faster dropout (shorter retention in MMT) was observed among patients who used pregabalin not orally (1.4 years, 95%CI 1.2–1.7) vs. (1.7 years, CI 1.6–1.8, p = .02), and those who used it not for pain (p = .024). Knowledge scores were higher among those tested positive for pregabalin (3.5 ± 1.7 vs. 2.9 ± 2.0, p = .04). Pregabalin is highly misused among MMT patients. Those who use it not for its indications, or not orally had a shorter retention in MMT, most likely not as a sole cause. “Ever users” knew more about pregabalin indications and risks. Monitoring and education on pregabalin are recommended.
AB - We examined motives for pregabalin misuse and the relation with knowledge on its risks among patients receiving MMT. A questionnaire was used to assess patients’ knowledge before and after an explanatory session. Responses were either “never-use” or “ever-use” (past, occasional, chronic). Pregabalin in urine was tested during 1 month, 4 months before, and 24 months after the explanatory session. Of 231 participants, 72 (31.2%) responded “ever-use” while 46 (19.9%) tested positive for pregabalin (42 (58.3%) of the “ever-use” and 4 (2.5%) of the “never-use” group). The ‘occasional’ subgroup had the highest proportion of non-prescribed pregabalin (75%), used it for recreational purpose (16.7%) and non-orally (41.7%). A faster dropout (shorter retention in MMT) was observed among patients who used pregabalin not orally (1.4 years, 95%CI 1.2–1.7) vs. (1.7 years, CI 1.6–1.8, p = .02), and those who used it not for pain (p = .024). Knowledge scores were higher among those tested positive for pregabalin (3.5 ± 1.7 vs. 2.9 ± 2.0, p = .04). Pregabalin is highly misused among MMT patients. Those who use it not for its indications, or not orally had a shorter retention in MMT, most likely not as a sole cause. “Ever users” knew more about pregabalin indications and risks. Monitoring and education on pregabalin are recommended.
KW - Pregabalin
KW - knowledge
KW - methadone maintenance treatment
KW - misuse
UR - http://www.scopus.com/inward/record.url?scp=85098569619&partnerID=8YFLogxK
U2 - 10.1080/02791072.2020.1861392
DO - 10.1080/02791072.2020.1861392
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33357129
AN - SCOPUS:85098569619
SN - 0279-1072
VL - 53
SP - 238
EP - 246
JO - Journal of Psychoactive Drugs
JF - Journal of Psychoactive Drugs
IS - 3
ER -